Vol. 5, Issue 4, Part A (2019)

Abstract: Scientists from time to time have suggested multiple classifications and renamed Odontogenic keratocyst (OKC). Recently WHO classified OKC and renamed it as Keratocystic Odontogenic Tumor (KCOT) based on its behavior and aggressiveness. Studies have concluded that the role of various factors responsible to be calling it as a neoplasm, some of which are Loss of Heterozygosity (LOH), involvement of PTCH1 gene and expression of various factors and proteins. It is now well established that the OKC is an aggressive cystic lesion that has a propensity for recurrence if not adequately removed and may undergo malignant changes. In spite of several classifications and nomenclature the clinicians still have to face difficulties in the management of this commonly found jaw lesion. This article is an effort to provide an overview for different various aspects of OKC with emphasis on nomenclature and molecular. As these lesions included into a neoplasm hence should be treated as same. Various newer inhibitor drugs have been introduced for treatment of cancer might be useful for the treatment of aggressive cystic lesion like KCOT.